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Acquired C1 inhibitor deficiency (AAE) is a rare syn-
drome with features similar to those of hereditary angio­
edema (HAE), but differing in its later onset and lack 
of family history. AAE is characterized by increased 
consumption of C1 inhibitor associated with lympho­
proliferative or malignant disorders, autoimmune or 
infectious diseases (1, 2). 
In C1 inhibitor deficiency two different skin ma-
nifestations can be seen: angioedema and erythema 
marginatum. Erythema marginatum is a highly cha-
racteristic serpiginous, non­pruritic exanthema, also 
known as chicken wire erythema, reported by up to 
60% of patients (3). Erythema marginatum may precede 
or accompany the angioedema attack or it can be an 
isolated finding. 
Bradykinin is a key mediator in these angioedema 
attacks (4), and deposits of bradykinin have been iden-
tified in a skin biopsy of erythema marginatum (5). 
Icatibant, a bradykinin­B2­receptor antagonist, is an 
emerging treatment option in C1 inhibitor deficiency, 
licensed in Europe in 2008 for the indication HAE. 
CASE REPORT
A 61­year­old man was referred to us in 2008 with 
a history of swellings of his hands, feet and external 
genitalia every 3–4 months for the last 4 years. The 
attacks were typically preceded or accompanied by a 
serpiginous erythema. During the last year his swellings 
had become more frequent and he had experienced re-
current, disabling angioedema of his face and painful 
abdominal attacks. Treatment with antihistamines and 
corticosteroids had no effect and the swellings disap-
peared after 1–3 days with or without treatment. A sus-
picion of C1 inhibitor deficiency was raised and blood 
tests revealed a functional C1 inhibitor value of 48%, 
but normal C1 inhibitor, C1q and C4c concentrations. 
At re­test one year later, functional C1 inhibitor value 
was < 20% (70–130), C1 inhibitor concentration was 
0.06 g/l (normal values 0.21–0.39), C4c was 0.08 g/l 
(0.10–0.40) and C1q was < 0.01 µg/l (0.29–0.60) and 
AAE was diagnosed. Auto­antibodies (IgM and IgG) 
against C1 inhibitor were detected in high titres. Our 
patient had been treated for a superficial malignant me-
lanoma 2 years previously, but no signs of relapse could 
be demonstrated. Work­up with blood tests including 
ANA, chest X­ray, ultrasonography of the abdomen 
and positron emission tomography – computed tomo-
graphy (PET­CT) was unremarkable. The patient started 
prophylactic treatment with tranexamic acid 1000 mg 
tid in April 2009 with sparse effect and frequency of 
attacks steadily increased until he needed C1 inhibitor 
concentrate (Berinert®, CSL Behring, Marburg, Ger-
many) almost weekly for acute attacks. Almost every 
angioedema attack was preceded or accompanied by 
erythema marginatum, disappearing 3–4 h after the 
injection of 1500 units of C1 inhibitor concentrate. 
In December 2009, he presented with a scrotal angio­
edema of 1­day duration and a concomitant erythema 
marginatum on his neck and trunk. He received sub-
cutaneous treatment with icatibant (Firazyr®, Jerini, 
Berlin, Germany) 30 mg, and the erythema marginatum 
surprisingly disappeared within 15–30 min (Fig. 1). 
The scrotal edema started to decrease after 4 h. Besi-
des a transient slightly painful urticarial injection­site 
reaction (Fig. 2), no side­effects to the drug have been 
observed in this patient. Until now he has received a 
total of 11 individual treatments with icatibant for facial, 
tongue and abdominal swellings, with a fast treatment 
response in all situations. In the last four attacks local 
injection­site reactions and erythema marginatum were 
not seen. At the time of writing he develops angioedema 
every 3–4 weeks. No underlying cause of his AAE has 
yet been identified.
DISCUSSION
The prophylactic and symptomatic management of AAE 
correspond to treatment of HAE, but the treatment re-
sponse may be different. AAE patients are often resistant 
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Fig. 1. Erythema marginatum (a) before and (b) 30 min after treatment with 
icatibant, a bradykinin­B2­receptor antagonist.
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to attenuated androgens, thus the first choice for angio­
edema prophylaxis is an antifibrinolytic agent (1, 2). 
C1 inhibitor concentrate has been the treatment 
of choice for angioedema attacks in AAE patients; 
however, some patients have autoantibodies against 
C1 inhibitor and become highly resistant, thus doses 
have to be increased several times in order to obtain a 
clinical response. The effect of icatibant on angioedema 
attacks in AAE has been published in three case reports 
earlier this year; however, in none of these patients was 
erythema marginatum described (6–8). The drug is not 
yet licensed in AAE, but its mechanism of action also 
makes icatibant a treatment choice in AAE.
This is the first report showing treatment response of 
icatibant on erythema marginatum confirming bradykinin 
as a key mediator, not only in angioedema attacks of C1­
inhibitor deficiency, but also in erythema marginatum. 
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Fig. 2. Urticarial reaction at the injection site of icatibant.
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